Ahmedabad-based Cadila Pharmaceuticals is looking for global tie-ups to market its new patented product — Polycap — a combination of five medicines that prevents heart attack.
“We have already got regulatory approval to launch Polycap in India and for launching it in overseas market. Cadila is looking for tie-ups with global drug firms,” said Arun Masi, vice-president, medical services.
The company had the capability of launching the drug in Indian market, but in markets such as the US and Europe, it required partnership with other firms, he said adding, “Partnership with global players is also required for getting regulatory approval and market access in developed countries.”
Cadila has already initiated talks with some multinational firms, he said.